文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

延长输注β-内酰胺治疗、死亡率及后续抗生素耐药性:革兰阴性菌血流感染住院成人研究

Extended-Infusion β-Lactam Therapy, Mortality, and Subsequent Antibiotic Resistance Among Hospitalized Adults With Gram-Negative Bloodstream Infections.
PubMed 文献 · JAMA Netw Open · 2024-07-01
一句话结论在革兰阴性菌血流感染住院成人中,延长输注β-内酰胺与90天死亡率降低相关(aOR 0.71),但导管并发症和因不良事件停药风险增加。

该多中心队列研究纳入2019年在美国24家医院连续收治的革兰阴性菌血流感染成人,比较延长输注(≥3小时)与间歇输注(≤1小时)β-内酰胺治疗。经1:3倾向性评分匹配后,延长输注组90天死亡风险更低(aOR 0.71,95%CI 0.52-0.97),但导管并发症(aOR 3.14)和因不良事件停药(aOR 3.66)风险更高。分层分析显示生存获益仅见于重症患者或最低抑菌浓度升高(所用药物的中介范围)者。耐药出现率两组相似(2.9% vs 7.2%,P=0.35)。

要点

  • 在革兰阴性菌血流感染住院成人中,延长输注β-内酰胺与90天死亡风险降低相关(aOR 0.71,95%CI 0.52-0.97)。
  • 生存获益仅见于重症患者或感染最低抑菌浓度升高(所用药物的中介范围)者,其他人群的潜在优势仍不明确。
  • 延长输注组导管并发症风险增加(aOR 3.14,95%CI 1.66-5.96)。
  • 延长输注组因不良事件(如急性肾损伤、血细胞减少、癫痫发作)停药的风险增加(aOR 3.66,95%CI 1.68-7.95)。
  • 耐药出现率在延长输注组与间歇输注组分别为2.9% vs 7.2%(P=0.35),差异未达统计学显著。

适用人群与场景

  • 2019年1月1日至2019年12月31日在美国24家医院连续收治的革兰阴性菌血流感染成人。
  • 接受延长输注β-内酰胺(≥3小时)者与接受相同药物间歇输注(≤1小时)者进行比较。

诊断标准与关键阈值

  • 延长输注β-内酰胺定义为输注时间≥3小时;间歇输注β-内酰胺定义为输注时间≤1小时。
  • 耐药出现定义为治疗指数革兰阴性菌血流感染所用β-内酰胺的最低抑菌浓度较基线升高≥4倍。

研究设计与关键结果

  • 研究类型为队列研究,纳入4861例患者,其中男性2547例(52.4%),中位年龄67岁(IQR 55-77)。
  • 经1:3倾向性评分匹配后,延长输注组352例,间歇输注组1056例,共1408例;至第90天共373例(26.5%)死亡。
  • 延长输注组死亡风险更低(aOR 0.71,95%CI 0.52-0.97)。
  • 分层分析显示生存获益仅见于重症患者或最低抑菌浓度升高(所用药物的中介范围)者。
  • 延长输注组导管并发症风险增加(aOR 3.14,95%CI 1.66-5.96)。
  • 延长输注组因不良事件(如急性肾损伤、血细胞减少、癫痫发作)停药风险增加(aOR 3.66,95%CI 1.68-7.95)。
  • 耐药出现率在延长输注组与间歇输注组分别为2.9% vs 7.2%(P=0.35),差异未达统计学显著。

证据类型、等级与局限

  • 证据类型:队列研究(多中心,24家美国医院)。
  • 局限:作者指出,延长输注在其他人群中的潜在优势仍不明确;耐药后续出现需在更大队列中研究。

对床旁实践的改变

  • 对于革兰阴性菌血流感染的住院成人,尤其是重症患者或感染最低抑菌浓度升高(所用药物的中介范围)者,延长输注β-内酰胺可能降低90天死亡风险(aOR 0.71)。
  • 使用延长输注β-内酰胺时需权衡导管并发症(aOR 3.14)和因不良事件停药(aOR 3.66)的风险增加。
  • 耐药出现率两组相似(2.9% vs 7.2%,P=0.35),但作者认为需在更大队列中进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Current evidence is conflicting for associations of extended-infusion β-lactam (EI-BL) therapy with clinical outcomes.

OBJECTIVE: To investigate the association of EI-BL therapy with survival, adverse events, and emergence of antibiotic resistance in adults with gram-negative bloodstream infections (GN-BSI).

DESIGN, SETTING, AND PARTICIPANTS: This cohort study of consecutive adults with GN-BSI admitted to 24 United States hospitals between January 1, 2019, and December 31, 2019, receiving EI-BL were compared with adults with GN-BSI receiving the same agents as intermittent infusion β-lactam (II-BL; ≤1-hour infusions). Statistical analysis was performed from January to October 2023.

EXPOSURES: EI-BL (ie, ≥3-hour infusion).

MAIN OUTCOMES AND MEASURES: EI-BL and II-BL groups underwent 1:3 nearest-neighbor propensity score matching (PSM) without replacement. Multivariable regression was applied to the PSM cohort to investigate outcomes, all censored at day 90. The primary outcome was mortality; secondary outcomes included antibiotic adverse events and emergence of resistance (≥4-fold increase in the minimum inhibitory concentration of the β-lactam used to treat the index GN-BSI).

RESULTS: Among the 4861 patients included, 2547 (52.4%) were male; and the median (IQR) age was 67 (55-77) years. There were 352 patients in the EI-BL 1:3 PSM group, and 1056 patients in the II-BL 1:3 PSM group. Among 1408 PSM patients, 373 (26.5%) died by day 90. The odds of mortality were lower in the EI-BL group (adjusted odds ratio [aOR], 0.71 [95% CI, 0.52-0.97]). In a stratified analysis, a survival benefit was only identified in patients with severe illness or elevated minimum inhibitory concentrations (ie, in the intermediate range for the antibiotic administered). There were increased odds of catheter complications (aOR, 3.14 [95% CI, 1.66-5.96]) and antibiotic discontinuation because of adverse events (eg, acute kidney injury, cytopenias, seizures) in the EI-BL group (aOR, 3.66 [95% CI, 1.68-7.95]). Emergence of resistance was similar in the EI-BL and II-BL groups at 2.9% vs 7.2%, respectively (P = .35).

CONCLUSIONS AND RELEVANCE: In this cohort study of patients with GN-BSI, EI-BL therapy was associated with reduced mortality for patients with severe illness or those infected with nonsusceptible organisms; potential advantages in other groups remain unclear and need to be balanced with potential adverse events. The subsequent emergence of resistance warrants investigation in a larger cohort.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Karaba SM, Cosgrove SE, Lee JH, et al. Extended-Infusion β-Lactam Therapy, Mortality, and Subsequent Antibiotic Resistance Among Hospitalized Adults With Gram-Negative Bloodstream Infections. JAMA Netw Open. 2024. PMID: 38954416. doi:10.1001/jamanetworkopen.2024.18234

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。